Page 1

Navamedic ASA : Q3 2021 financial results THU , NOV 04 , 2021 08:00 CET Oslo , 4 November 2021 - Navamedic ASA ( OSE : NAVA ) grew revenues by 12 % in the third quarter of 2021 compared to the same quarter last year . The company reported revenues of NOK 63.6 million in the third quarter of 2021 with an EBITDA of NOK 3.7 million , driven by underlying growth in the portfolio and Mysimba® in particular . The company reiterates its mid - term ambition of building a NOK 500 million company through organic growth . " Our portfolio of specialty pharma and consumer health products continue to grow with particularly strong performance for the obesity medicine Mysimba , which grew by 77 % in the third quarter . We expect the high demand for Mysimba to continue going forward , further fueled by the conditional reimbursement in Finland and roll - out of our successful patient support program , helping obesity patients across the Nordics to succeed in their treatment , " says Kathrine Gamborg Andreassen , Chief Executive Officer of Navamedic ASA , and continues . " We are also pleased to see the strong performance of our portfolio of antibiotics products , displaying solid traction on tenders compared to plan with new tenders won in several countries . " Revenues in the third quarter of 2021 were NOK 63.6 million ( NOK 56.8 million in the third quarter of 2020 ) . The gross margin was 38.9 % ( 31 % ) , while the EBITDA was NOK 3.7 million ( 3.8 ) . In YTD 2021 , revenues grew by 21.8 % compared to the same period last year , up from NOK 154.6 million to NOK 188.3 million , while EBITDA was NOK 10.6 million , up from NOK 2.4 million in the same period last year . Navamedic will launch products in at least one country in each launch window going forward . The company targets 20 % annual growth from 2021 and reiterates its mid- term ambition of building a NOK 500 million company through organic growth with strong gross margins and underlying profitability . Navamedic is hosting a webcast presentation of the third quarter 2021 financial results , Thursday 4 November at 08.45 CET . The presentation will be held at Sparebank 1 Markets in Olav V's gate 5 in Oslo as well as via webcast on www.navamedic.com/investors/financial-results under ' 2021 ' . Representatives from Navamedic will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand . EBITDA and other alternative performance measures ( APMs ) are defined and reconciled to the IFRS financial statements as a part of the APM section of the attached third quarter 2021 presentation on slide 22 . For further information , please contact : Kathrine Gamborg Andreassen , CEO , Navamedic Mobile : +47 951 78 680 E - mail : kathrine@navamedic.com Lars Hjarrand , CFO , Navamedic Mobile : +47 917 62 842 E - mail : lars.hjarrand@navamedic.com Navamedic ASA is a Nordic pharma company and reliable provider of high - quality products , delivered to hospitals and through pharmacies , meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform , leading category competence and local knowledge . Navamedic is present in all the Nordic countries , the Baltics and Benelux , with sales representation in the UK and Greece . Navamedic is headquartered in Oslo , Norway , and listed on the Oslo Stock Exchange ( ticker : NAVA ) . For more information , please visit www.navamedic.com This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act .